Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 07 Sep 2021
TGA approves new cancer medicine
7 September 2021 - Luspatercept (Reblozyl) is used to treat patients with certain transfusion-dependent anaemias. ...
Posted by Michael Wonder on 07 Sep 2021
Singapore's health care system: key features, challenges, and shifts
2 September 2021 - Since Singapore became an independent nation in 1965, the development of its health care system has been ...
Posted by Michael Wonder on 07 Sep 2021
U.S. FDA accepts for priority review supplemental new drug application for Oxbryta (voxelotor) for the treatment of sickle cell disease in children ages 4 to 11
7 September 2021 - New drug application for Oxbryta dispersible tablets also accepted for priority review. ...
Posted by Michael Wonder on 07 Sep 2021
Reimbursement uncertain for Piqray targeting PIK3CA mutation in breast cancer
7 September 2021 - The first and only targeted therapy to treat hormone receptor positive and human epidermal growth factor ...
Posted by Michael Wonder on 07 Sep 2021
To lower drug costs, define ‘cost’ to mean net cost after rebates
7 September 2021 - In what could be a turning point in the prescription drug debate, President Biden has made ...
Posted by Michael Wonder on 07 Sep 2021
Landmark new medicines agreements to bring significant benefits for Australian patients
7 September 2021 - Australians will have more affordable, improved and guaranteed access to medicines under landmark long-term strategic agreements between ...
Posted by Michael Wonder on 07 Sep 2021
New strategic agreements with the medicines industry
7 September 2021 - The Australian Government has entered into new strategic agreements with Medicines Australia and the Generic and ...
Posted by Michael Wonder on 06 Sep 2021
JW Therapeutics announces NMPA approval of relmacabtagene autoleucel injection in China
6 September 2021 - The first CAR-T product independently developed in China and approved as a Category 1 biologics product, and ...
Posted by Michael Wonder on 06 Sep 2021
UK MHRA grants GenSight Biologics’ Lumevoq ophthalmic gene therapy Promising Innovative Medicine Designation
6 September 2021 - GenSight Biologics today announced that its gene therapy Lumevoq has been granted Promising Innovative Medicine designation by ...
Posted by Michael Wonder on 06 Sep 2021
EMA evaluating data on booster dose of COVID-19 vaccine Comirnaty
6 September 2021 - EMA has started evaluating an application for the use of a booster dose of Comirnaty to be ...
Posted by Michael Wonder on 06 Sep 2021
Leap forward for patients accessing medicines
7 September 2021 - Medicines Australia has secured a 5 year strategic agreement with the Federal Government, centered on earlier ...
Posted by Michael Wonder on 06 Sep 2021
Health economic assessment of Sarclisa in multiple myeloma
6 September 2021 - TLV has produced a health economic assessment for the regions for the drug Sarclisa (isatuximab) in combination ...
Posted by Michael Wonder on 06 Sep 2021
Democrats’ plans to introduce prescription drug pricing reform face formidable obstacles
6 September 2021 - For years, reducing prescription drug prices has been a policy goal of (mostly Democratic) legislators at the ...
Posted by Michael Wonder on 06 Sep 2021
Congress “concerned by apparent anomalies” around FDA’s approval of Aduhelm
6 September 2021 - Congress demands more information from the FDA on its controversial approval of Biogen’s Alzheimer’s drug and its ...
Posted by Michael Wonder on 06 Sep 2021
Statement on Moderna COVID-19 vaccine
6 September 2021 - Medicines Australia welcomes the TGA provisional approval for the COVID-19 vaccine, Spikevax (Moderna) for Australia. The ...